Results 81 to 90 of about 1,283,944 (322)

Economic Evaluation Plan (EEP) for A Very Early Rehabilitation Trial (AVERT): An international trial to compare the costs and cost-effectiveness of commencing out of bed standing and walking training (very early mobilization) within 24 h of stroke onset with usual stroke unit care [PDF]

, 2016
Rationale: A key objective of A Very Early Rehabilitation Trial is to determine if the intervention, very early mobilisation following stroke, is cost-effective.
Fiona Ellery, Helen Dewey, Janice M Collier, Julie Bernhardt, Kiu Tay-Teo, Lauren Sheppard, Leonid Churilov, Marj Moodie, null null, Olivia Wu   +9 more
core   +1 more source

Molecular imaging predicts trastuzumab‐deruxtecan (T‐DXd) response in head and neck cancer xenograft models

Molecular Oncology, EarlyView.
Trastuzumab‐deruxtecan, a HER2‐targeting antibody‐drug conjugate, shows promising antitumor activity in head and neck squamous cell carcinoma with low HER2 expression. In vitro and in vivo studies demonstrated dose‐dependent cell death and tumor growth reduction in low HER2‐expressing cell lines, which correlated with drug accumulation measured using a
Abdullah Bin Naveed, Lucas Mani, Muhammad Bilal Mirza, Ashtyn McAdoo, Takahito Kondo, Hidenori Tanaka, Nicole Meeks, Eben Rosenthal, Marisa Hom   +8 more
wiley   +1 more source

Calibration of Quality-Adjusted Life Years for Oncology Clinical Trials [PDF]

Journal of Pain and Symptom Management, 2014
Quality-adjusted life year (QALY) estimation is a well-known but little used technique to compare survival adjusted for complications. Lack of calibration and interpretation guidance hinders implementation of QALY analyses.We conducted simulation studies to assess the impact of differences in survival, toxicity rates, and utility values on QALY results.
Jeff A. Sloan, Daniel J. Sargent, Paul J. Novotny, Heidi Nelson, Randolph S. Marks, Paul A. Decker   +5 more
openaire   +2 more sources

EMT‐associated bias in the Parsortix® system observed with pancreatic cancer cell lines

Molecular Oncology, EarlyView.
The Parsortix® system was tested for CTC enrichment using pancreatic cancer cell lines with different EMT phenotypes. Spike‐in experiments showed lower recovery of mesenchymal‐like cells. This was confirmed with an EMT‐inducible breast cancer cell line.
Nele Vandenbussche, Renske Imschoot, Béatrice Lintermans, Lode Denolf, Joachim Taminau, Charlotte Fieuws, Geert Berx, Kris Gevaert, Kathleen B. M. Claes   +8 more
wiley   +1 more source

Peer effects in health valuation: the relation between rating of contemporaries’ health and own health

Health and Quality of Life Outcomes, 2018
Background Most health valuation studies assume that individuals’ health valuations do not depend on social comparisons. However, there is some evidence that this assumption is not satisfied in practice.
Arthur E. Attema, Werner B. F. Brouwer, Jose Luis Pinto Prades   +2 more
doaj   +1 more source

Where’s WALY? : A proof of concept study of the ‘wellbeing adjusted life year’ using secondary analysis of cross-sectional survey data [PDF]

, 2016
Background The Quality-Adjusted Life Year (QALY) is a measure that combines life extension and health improvement in a single score, reflecting preferences around different types of health gain.
A Appels, A Clarke, A Zajacova, Aileen Clarke, Chris Stinton, D Papaioannou, D Watson, David Jenkinson, DM Crone, EL Idler, EuroQoL Group, F Taggart, FA Huppert, G Lindsay, GR Barton, H Maheswaran, HJ Braiden, HM Agt van, J Brazier, J Brazier, J Collins, J Powell, J Schnittker, J Tosh, JA Johnson, Jason Madan, JHP Hoffmeyer-Zlotnik, JM Haro, KB DeSalvo, L Longworth, L Longworth, M Bharmal, M Herdman, MF Janseen, MJ Crawford, MS Kaplan, N Odou, NP Hurst, P Dolan, P Kind, P Kind, R Brooks, R Core Team, R Rabin, R Tennant, Rebecca Johnson, Sarah Stewart-Brown, SI Saarni, Sian Taylor-Phillips, X Robin, Y Chida   +50 more
core   +3 more sources

Tumor clusters with divergent inflammation and human retroelement expression determine the clinical outcome of patients with serous ovarian cancer

Molecular Oncology, EarlyView.
Analysis of treatment‐naïve high‐grade serous ovarian carcinoma (HGSOC) and control tissues for ERVs, LINE‐1 (L1), inflammation, and immune checkpoints identified five clusters with diverse patient recurrence‐free survivals. An inflammation score was calculated and correlated with retroelement expression, where one novel cluster (Triple‐I) with high ...
Laura Glossner, Markus Eckstein, Christoph Mark, Matthias W. Beckmann, Arndt Hartmann, Pamela L. Strissel, Reiner Strick   +6 more
wiley   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

Methods for the estimation of the National Institute for Health and Care Excellence cost-effectiveness threshold

Health Technology Assessment, 2015
Background: Cost-effectiveness analysis involves the comparison of the incremental cost-effectiveness ratio of a new technology, which is more costly than existing alternatives, with the cost-effectiveness threshold.
Karl Claxton, Steve Martin, Marta Soares, Nigel Rice, Eldon Spackman, Sebastian Hinde, Nancy Devlin, Peter C Smith, Mark Sculpher   +8 more
doaj   +1 more source

Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Moderate-to-Severe Plaque Psoriasis: The Chinese Healthcare System Perspective

Dermatology and Therapy, 2023
Introduction This study assessed the cost-effectiveness of secukinumab compared with other biologics (adalimumab, infliximab, ustekinumab, ixekizumab, guselkumab, and Yisaipu [etanercept biosimilar]) for moderate-to-severe plaque psoriasis from the ...
Jinsui Zhang, Zemin Xia, Wanjie Guo, Xiaoxiao Ren, Fang Liu, Gargi Ratnaparkhi, Amit Pagada, Subhashini Subramanian, Min Hu, Wen Chen   +9 more
doaj   +1 more source